avatrombopag + daratumumab + dexamethasone + eltrombopag + fostamatinib + mycophenolate mofetil + rituximab

This is a combination regimen consisting of seven distinct pharmaceutical agents, each with different mechanisms of action and indications. The drugs included are: - **Avatrombopag** and **Eltrombopag** (thrombopoietin receptor agonists) stimulate platelet production for the treatment of thrombocytopenia[1][5][6]. - **Daratumumab** (a monoclonal antibody targeting CD38) is primarily used in multiple myeloma. - **Dexamethasone** (a synthetic glucocorticoid corticosteroid) has anti-inflammatory and immunosuppressive effects. - **Fostamatinib** (a spleen tyrosine kinase inhibitor) is used for chronic immune thrombocytopenia. - **Mycophenolate mofetil** (an immunosuppressant that inhibits inosine monophosphate dehydrogenase) is commonly used to prevent organ rejection or treat autoimmune diseases. - **Rituximab** (a monoclonal antibody targeting CD20 on B cells) is indicated for various hematologic malignancies and autoimmune disorders. This combination does not correspond to any approved fixed-dose product or standard clinical regimen but represents a multi-agent protocol potentially designed for severe, refractory immune-mediated cytopenias or complex hematologic conditions. Each component acts via a distinct pathway affecting immune modulation, B-cell depletion, platelet stimulation, or suppression of autoantibody production.